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Abstract 
Antimicrobial resistance (AMR) poses a threat to global health and the economy. Rifampicin-
resistant Mycobacterium tuberculosis accounts for a third of the global AMR burden. Gaining the 
upper hand on AMR requires a deeper understanding of the physiology of resistance.  
AMR often results in the erosion of normal cell function: a fitness cost. Identifying intervention 
points in the mechanisms underpinning the cost of resistance in M. tuberculosis could play a pivotal 
role in strengthening future treatment regimens. We used a collection of M. tuberculosis strains 
providing an evolutionary and phylogenetic snapshot of rifampicin resistance and subjected them 
to genome-wide transcriptomic and proteomic profiling to identify key perturbations of normal 
physiology.   
We found that a rifampicin resistance-conferring mutation in RpoB imparts considerable gene 
expression changes, many of which are mitigated by a compensatory mutation in RpoC. 
However, our data also provide evidence for pervasive epistasis: the same resistance mutation 
imposed a different fitness cost and functionally unrelated changes to gene expression in clinical 
strains from unrelated genetic backgrounds. Rather than functional changes in specific pathways, 
our data suggest that the fitness cost of rifampicin resistance stems from a misallocation of 
resources: the greater the departure from the wild type baseline proteome investment, the greater 
the fitness cost of rifampicin resistance in a given strain. We summarize these observations in the 
“Burden of Expression” hypothesis of fitness cost and provide evidence that it can be used for 
suppressing the emergence of rifampicin resistance. 
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Introduction 
Antimicrobials are one of the cornerstones of modern medicine
1
. The global increase of 
antimicrobial resistance (AMR) poses an existential threat, claiming an increasing number of lives 
and resources
2
. We currently have access to a wide array of antibiotics, but their efficacy is 
waning, making safeguarding existing and future drugs a high priority. Understanding the 
mechanisms and drivers of AMR
3
, including the underlying biology, will be key to that process. 
Antibiotics target essential bacterial processes. Modification of their targets is an important 
mechanism through which AMR emerges. It is therefore not surprising that AMR often comes 
with a fitness cost
4
. Fitness cost is a broad concept capturing any negative deviation in the 
proliferation of a mutant from its ancestor: for example, a decreased growth rate in vitro, or in the 
case of pathogens, a decreased ability to transmit or cause disease. The physiological basis for the 
cost of drug resistance seems to be dependent on the antibiotic, bacterial species and 
environment
5
 and is thus often unknown and likely to be multifaceted. One of the better studied 
examples is the cost of rifampicin resistance. Rifampicin targets the bacterial RNA polymerase 
(RNAP), and resistance to rifampicin is usually mediated by mutations in the β subunit of 
RNAP
6
. Several studies point to the rate of transcription, particularly as it pertains to the 
synthesis of ribosomal RNA and ribosomal proteins, as an important mediator of growth rate
7,8
. 
A slowing down of transcription is therefore the prime mechanistic candidate for the cost of 
rifampicin resistance
9,10
. The mechanism linking RNAP activity to ribosome biosynthesis 
provides a compelling explanation for the cost of rifampicin resistance in rapidly dividing bacteria 
such as Escherichia coli and Pseudomonas aeruginosa whose growth relies on the rapid replenishment 
of biosynthetic machinery lost through cell division
11
. Importantly, the fitness cost of rifampicin 
resistance can be mitigated or even reversed through the acquisition of secondary, compensatory 
mutations in the α, β and β’ subunits of RNAP that seem to restore normal enzyme function
9,12,13
.   
Rifampicin-resistant Mtb is one of the major causes of AMR-associated mortality globally, 
claiming an estimated 240,000 lives in 2016
14
, and unlike in fast-growing bacteria, the rate of 
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transcription does not seem to reflect the fitness cost of key rpoB mutations, measured either as 
growth rate in vitro or prevalence in the clinic
13,15,16
. While relative fitness does seem to determine 
the clinical success of rifampicin-resistant Mtb
17
, and compensatory mutations are frequently 
found in settings with a high burden of drug resistant TB
18-21
, the basis for the fitness cost of 
rifampicin resistance remains unknown in Mtb. Understanding the mechanism by which rpoB 
mutations impair normal Mtb physiology could help identify new intervention points, through 
which we could stem the tide of existing and emergent rifampicin resistance. 
We used the known ability of mutations in the beta barrel double ψ (BBDP) domain of the β’ 
subunit of RNAP to compensate for the fitness cost of resistance mutations occurring in the β 
subunit in Mtb  as a starting point
12,13,22
. Compensatory mutations improve patient to patient 
transmission of rifampicin-resistant strains
19
, and partially reverse biochemical changes imparted 
on RNAP by rifampicin-resistance mutations
12,13
. We hypothesise that the same would be true for 
gene expression differences. Leveraging the knowledge of the role of RpoC mutations, we used 
transcriptomic and proteomic expression profiling to identify the signature of compensation and 
therefore infer the likely mediators of fitness cost in a collection of strains derived from a drug-
susceptible clinical isolate (see Figure 1). Our findings point to the idiosyncratic consequences of 
expressional dysregulation as a key factor conferring a fitness cost to rifampicin resistance in Mtb. 
We expanded on this observation by profiling the expression signature of rifampicin resistance in 
a panel of genetically diverse clinical isolates sharing the same rifampicin resistance-conferring 
mutation: RpoB Ser450Leu. While we found very little evidence for a shared expression signature 
of rifampicin-resistance across the tested strain pairs, we show a correlation between the fitness 
cost of the rifampicin-resistance conferring mutation and the extent to which its presence imparts 
a deviation from the proteome composition of the wild-type. Finally, we show that this 
correlation could be exploited to suppress the emergence of rifampicin resistance. 
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Results 
Compensatory mutations mitigate resistance-imposed expression changes 
Physiological changes incurred by a fitness cost are likely to manifest as deviations in gene 
expression. Since mutations in the BBDP domain of the β’ subunit of RNAP mitigate the fitness 
cost of rifampicin-resistance mutations in Mtb
12,13,22
 they should also impact and therefore 
highlight expression changes that are relevant to the understanding of fitness cost of rifampicin 
resistance. 
We previously reported the result of a directed evolution experiment in which we identified a 
mutation in the BBDP domain: RpoC Leu516Pro as a putative compensatory mechanism for the 
fitness cost of the rifampicin-resistance conferring mutation RpoB Ser450Leu in a clinical 
isolate
18
. The strains generated by that study comprise the original drug-susceptible isolate (DS), 
its laboratory-derived rifampicin-resistant mutant (RpoB Ser450Leu, RifR) and the resulting 
evolved strains obtained by serial passage in the absence of rifampicin for 200 generations (DS
evo
 
and RifR
evo
, respectively, see Figure 1A). Together these strains offer a representative snapshot of 
the evolutionary process that passes through the initial emergence of (costly) drug resistance and 
leads to the establishment of a mature drug-resistant strain whose fitness is indistinguishable 
from its drug susceptible ancestor. We therefore hypothesised that comparative transcriptomic 
and proteomic expression profiling of these strains will allow us to determine the signature of the 
fitness cost associated with rifampicin resistance. 
First, we determined the relative fitness of RifR. Using a mixed effect linear regression model to 
analyse growth assays, we noted a 26.4% decrease (CI
95%
: 21.5 – 31.0%, p < 0.001) in the growth 
rate of RifR when compared to DS. The comparison of their evolved counterparts – DS
evo
 and 
RifR
evo
 – showed no significant differences (-1.2%, CI
95%
: -10.8 – 7.1%, p = 0.814), illustrating the 
fact that RpoC Leu516Pro does indeed compensate the fitness cost of rifampicin resistance.  
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We aimed to identify differences in the baseline, unperturbed, gene expression as a proxy for 
describing the biological basis for reduced fitness in RifR. We sampled actively growing bacterial 
cultures of each of the four strains, extracting total RNA and protein to be profiled using RNA 
sequencing (RNAseq) and sequential window acquisition of all theoretical mass spectra 
(SWATH-MS),  respectively (see Figure 1B). In total, we were able to obtain RNA transcript 
counts for all present regions of the Mtb genome and reliably quantify 2,886 proteins across our 
samples (Supplementary Figure 1). We used differential expression analysis to test our hypothesis 
that the compensatory mutation RpoC Leu516Pro had the net effect of reversing, at least 
partially, the expression changes brought about by the rifampicin resistance mutation RpoB 
Ser450Leu. We named this trend a “signature of compensation” – see Figure 2A and we derived 
it by identifying genes that are uniquely differentially expressed in RifR compared to the other 
three strains in our dataset. To maximise the probability of identifying the signature of 
compensation, we chose an inclusive definition of differential expression: a p-value of less than 
0.05 after adjusting for multiple testing (see Methods). In keeping with our inclusive approach, 
we also deliberately did not use an effect size threshold (e.g. minimum log-fold change).  
Using these criteria, we identified 536 transcripts that could be involved in the cost of resistance. 
289 transcripts were less abundant and 247 were more abundant in RifR compared to the other 
samples. Similarly, 536 proteins showed a significant signature of compensation: 260 proteins 
were more and 276 were less-abundant in RifR (see Figure 2B). Gene set enrichment analysis of 
the transcriptomic and proteomic data pointed to iron homeostasis being significantly affected. 
Specifically, it indicated a higher expression, in RifR, of genes that are repressed by the iron-
dependent regulator (IdeR, Rv2711) in iron replete conditions. Among them, there was a 
significant enrichment of genes involved in polyketide and non-ribosomal peptide synthesis, 
which include the biosynthetic machinery for the sole Mtb siderophore: mycobactin (see 
Supplementary Figure 2-4). These changes suggested that RifR faced a shortage of iron in our 
experimental conditions. 
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The availability of iron is an essential requirement for Mtb growth, both in culture and during 
infection, and iron acquisition systems are therefore key virulence factors
23-25
. Hence, an increased 
requirement for iron could manifest itself as a loss of relative fitness. The fact that RpoB 
Ser450Leu led to a modification of the expression of genes involved in iron homeostasis and that 
RpoC Leu516Pro reversed the effect provides a compelling alternative mechanism underpinning 
the apparent fitness cost of rifampicin resistance. If the disruption of iron homeostasis drives 
fitness cost, we would expect that iron supplementation should mitigate the relative cost of RpoB 
Ser450Leu. Furthermore, based on the expression profile, we expected that RifR should produce 
more mycobactin at baseline than DS, potentially influencing the overall growth rate of the 
mutant.  
We addressed the first hypothesis by comparing growth rates of RifR and DS in the presence or 
absence of 10 µM hemin – an additional source of iron that is by itself sufficient to support the 
growth of a mutant defective in mycobactin biosynthesis. Importantly, hemin and mycobactin 
provide two separate routes of iron uptake, which allows us to side-step issues that might emerge 
from deficient iron transport
23
. The presence of hemin did not change the cost of RifR, which we 
calculated to be 18.6% in the absence and 20.9% in the presence of hemin for this experiment 
(Mixed effect linear model, p = 0.737).  Similarly, hemin did not impact the growth rate of DS (- 
4.7%, CI
95%
: -16.3 – 2.3%, p = 0.128). In summary, iron did not appear to limit the growth of 
RifR under normal conditions.  
Next, we addressed the production of mycobactin. We prepared whole cell extracts from DS and 
RifR grown in both, normal medium and medium supplemented with 10 µM hemin. We found 
that on average RifR produced more mycobactin than DS, corroborating the physiological 
relevance of the increased baseline expression of mycobactin biosynthesis genes. We also 
observed a slight decrease in the production of mycobactin in bacteria grown in the hemin-
supplemented medium, pointing to a modification of the expression of mycobactin biosynthesis 
cluster in response to iron (See Figure 3). Given that the growth rate was not affected by the 
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presence of hemin, these findings suggest that mycobactin itself does not modulate the growth 
rate of the mutant. It is therefore possible that the higher expression of the biosynthetic cluster 
itself might impart a fitness cost. 
Interestingly, while significantly enriched, only half of the genes reported to be repressed by 
IdeR
26
 in iron-replete conditions were part of the signature of compensation (22 out of 40 genes). 
This prompted us to take a closer look at the IdeR regulon and its regulation. We took advantage 
of recent studies modelling the global gene regulation in Mtb
27-29
. We reconstructed the genome-
wide gene regulatory network and extracted the immediate neighbours of IdeR- and iron-
responsive genes
28
. There were 7 expression modules that contained at least 3 genes that are part 
of the IdeR regulon (Figure 3, black diamonds). Together, these modules covered 82.5% of all 
the IdeR-repressed genes, and with the exception of Module 4 (Figure 3), none of the modules 
included IdeR-independent iron-responsive genes. All the genes that we identified as candidates 
for compensation belonged to Modules 1-4, while none of the genes included in the other 
modules were found to be differentially expressed in RifR. A key difference among modules was 
that IdeR-regulated genes represented more than half of all the genes in modules affected by 
compensation but fewer than half in those that were not part of the “signature of compensation”. 
Mapping proteomic data onto the same expression network produced similar results (see 
Supplementary Figure 5). Interestingly, few of the IdeR-independent iron-responsive genes were 
part of the signature of compensation. This pattern implies a modulation of the canonical 
function of IdeR, either through regulatory inputs from other transcription factors, or some 
other mechanism.  
These results supported our hypothesis that mutations in rpoB impart changes to the baseline 
expression profile of Mtb that could be reversed in the presence of a compensatory mutation in 
rpoC. Combining the expression data with our findings that iron supplementation and mycobactin 
levels did not affect RifR growth rates, we concluded that the transcriptional changes were not 
driven by the demand for iron. Instead, these changes might be a reflection of a dysfunction of 
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RNAP – e.g. differences in promoter specificity or modified interaction with IdeR, whose 
downstream consequences may impose a fitness effect. For example, as the mycobactin 
biosynthesis cluster comprises several large proteins, their excessive production could represent a 
drain on the cell’s resources. If true, we would expect such effects to be universal across all Mtb 
strains carrying this rpoB mutation.  
The impact of RpoB Ser450Leu is shaped by epistasis 
We wanted to test the hypothesis that higher expression of the mycobactin biosynthetic cluster is 
a general feature of rifampicin resistance in Mtb and therefore the underlying cause of its fitness 
cost. To do so, we generated RpoB Ser450Leu mutants in five genetically diverse clinical isolates 
belonging to two different Mtb lineages and profiled them. Globally, Mtb can be grouped into 
seven distinct genetic lineages each with a specific geographic distribution
30
. Mtb lineages can 
differ in their interaction with the human host, the dynamics of disease progression, and also in 
their apparent propensity to acquire drug resistance
31,32
. We chose strains belonging to Lineage 1 
and 2, because of their large phylogenetic separation (see Supplementary Figure 6) and more 
importantly, because drug resistance is often associated with Lineage 2 and relatively rare in 
Lineage 1
33
. We expected that the comparison of the transcriptome and proteome between the 
Ser450Leu mutants and their cognate wild type ancestor would allow us to identify general 
patterns of fitness cost linked to this mutation. 
It is important to note that this comparison did not include any compensated strains, i.e. strains 
carrying mutations in the BBDP domain. We were therefore unable to focus our analysis 
exclusively on genes whose expression was corrected by the presence of an rpoC mutation. 
Nonetheless, direct comparison of RifR and DS is virtually indistinguishable from the signature 
of compensation when considering IdeR-regulated genes and therefore serves as a reasonable 
proxy for our analyses (see Supplementary Figure 5). 
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We started by measuring the growth characteristics of the wild type isolates and the relative cost 
of the RpoB Ser450Leu mutation in the different strain backgrounds. The generation time varied 
from 22.7 h ( 
95%
CI: 20.8 – 25.0 h) to 31.0 h ( 
95%
CI: 29.3 – 35.1 h). The relative fitness cost of the 
RpoB Ser450Leu mutation differed as well, from a modest 2 % (mixed effect linear regression, p 
= 0.71) to a pronounced 27 % (mixed effect linear regression, p = 5.6 × 10
-6
). 
We obtained the expression profiles for each strain to check whether the pattern we identified for 
IdeR-repressed genes was a universal phenotype for RpoB Ser450Leu mutants. Analysing the 
transcriptomic data by performing a single comparison across the five strain pairs, we found that 
only 17.5% (7/40 genes) of the IdeR-repressed genes were significantly differentially expressed. A 
single gene belonging to the mycobactin biosynthesis cluster was included in that number. 
Proteomic analysis revealed a similar result – 17.1% (6/35 detected proteins) were found to be 
significantly differentially expressed across all strains, none of which belonged to the mycobactin 
biosynthesis cluster. None of the iron-homeostasis gene sets highlighted in the “signature of 
compensation” were significantly differentially expressed across all strains. Since these findings 
were contrary to our expectations, we stratified the analysis and mapped the differential 
expression results for each strain onto the IdeR- and iron-responsive gene network we collated 
earlier. These results echoed our combined analysis: the signature of compensation was not 
universal across the tested strains. N0155, which corresponds to “DS”, is the only strain to show 
a transcriptional profile consistent with the signature of compensation (see Figure 4A). Proteomic 
data corroborated this finding (see Supplementary Figure 7). It is important to note that these 
data represent an independent replication of the experiments, from which we derived the 
signature of compensation, showing that our original results are robust and reproducible. 
However, the absence of a coherent IdeR-responsive phenotype was clear evidence of epistasis 
and raised a broader question: are there any commonalities in the phenotypic manifestation of 
the RpoB Ser450Leu mutation among our set of strains? 
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To address this question we sought to identify expression modules
28
 whose membership was well 
represented among significantly differentially expressed genes in at least one pair-wise 
comparison between a rifampicin-resistant strain and its cognate drug-susceptible ancestor (see 
Methods for details). Using transcriptomic and proteomic data, we identified 33 expression 
modules that fitted our criterion (see Figure 4B). There was virtually no consensus across the 
strains in the transcriptional or translational response to the rpoB mutation. The only case where 
we observed partial agreement across genetic backgrounds concerned some of the modules 
controlled by the hypoxia-responsive regulator DosR
34
. As with modules containing IdeR iron-
repressed genes, we observed only partial regulon induction for DosR. Specific modules were 
clearly involved in the expression changes (either protein or transcript) in each background, but 
the impact of these was strain-specific. A complementary manifestation of this phenomenon 
comes from the global comparison of all rifampicin-resistant strains against all wild type strains, 
which highlighted a single module as enriched for significantly differentially expressed genes. 
Comparing the distribution of the effect sizes, as measured by the per-gene fold-changes in 
expression in the combined analysis and the pairwise comparisons for each strain, we saw a 
marked muting of the magnitude of differential expression in the former (see Supplementary 
Figure 8). This was likely due to the averaging effect of the combined analysis suppressing the 
contribution of the differential expression from individual strains. The magnitude of the 
expression change in pairwise comparisons was comparable across strains. 
Overall, we were able to identify a wealth of gene expression changes in our samples: as many as 
958 transcripts and 1914 proteins were observed to be differentially expressed in at least one 
comparison across our samples. On the level of individual genes, the transcriptome and to lesser 
extent the proteome of each strain were perturbed in their own private way (see Supplementary 
Figures 9&10), manifesting itself as the drug resistance iteration of the Anna Karenina principle
35
. 
Because the majority of those changes were specific to individual strains they were largely 
invisible if the comparison was made across all strain pairs. The fact that the same mutation can 
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have such profoundly different outcomes depending on the genetic context in which it occurs, is 
clear evidence of epistasis, and shows that natural genetic variation can fundamentally impact the 
physiological consequences and therefore evolution of drug resistance. Importantly, the impact of 
resistance on the expression profile of any two strains was found to be independent of the 
genetic distance between them (see Supplementary Figure 11). 
So far, we showed that the RpoB Ser450Leu causes a considerable re-organization of baseline 
gene expression, that this perturbation can be reversed by a compensatory mutation in RpoC and 
that the specific phenotypic manifestation was dependent on mutations that occurred more 
recently than those defining individual lineages. These findings were consistent with our 
observation that the same mutation imposed a different fitness cost to different strains. We 
therefore sought to find correlates of the varying fitness costs. 
Deviation from baseline expression correlates with the cost of rifampicin resistance 
Pleiotropic phenotypes of the kind described above are not normally addressed, however we 
wanted to explore whether the extent of the expression perturbations correlated with the varying 
fitness costs of Ser450Leu we observed in different genetic backgrounds. We reasoned that the 
cumulative impact on expression disruption, rather than the dysregulation of individual genes, 
would provide a conduit for a loss of fitness. 
In the first instance, we considered the correlation between the fitness cost of the rpoB mutation 
and the overall expression distance between the mutant and its cognate wild type strain (See 
Supplementary Figure 12). Through this approach, we were able to detect a relationship between 
cost and expression differences for the expressed proteins (R
2
 = 0.83, p = 0.031, ordinary least 
squares linear regression) but not RNA (R
2
 = 0.39, p = 0.258, ordinary least squares linear 
regression). Given that the correlation was stronger in the proteome compartment, and that the 
proteome compartment seemed more affected by resistance, we elaborated on our observation 
by incorporating a measure of physiological cost for each protein. We used two different metrics 
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for cost. In the simpler case we used the molecular weight of amino acids as proxy for the 
resource investment necessary to generate each protein
36
. We also used estimates of ATP cost for 
each amino acid in E. coli as a way to approximate the level of energy investment a bacterial cell 
makes when synthesising its proteome
37
. Both metrics showed that drug resistance imposes an 
additional physiological cost to the baseline proteome (Molecular Weight: Mann-Whitney U-test, 
p = 8.26 × 10
-4
, ATP equivalents: Mann-Whitney U-test, p = 4.50 × 10
-4
, see Supplementary 
Figure 13). Furthermore, this cost was negatively correlated with the relative fitness of the RpoB 
Ser450Leu mutation in a given strain background (ρ
s
 = - 0.90, p = 0.04) – the greater the 
deviation from the resource investment of the ancestral proteome, the larger the cost of the 
mutation (see Figure 5A). Growth rate and gene expression are not independent from each other. 
To test the possibility that the observed correlation may be an artefact of our analysis, we took 
advantage of the natural variation in growth rates of different drug-susceptible clinical isolates in 
our medium and compared them to the relative costs of expression (See Supplementary Figure 
14). We performed a pairwise comparison across all the tested strains and observed no 
statistically significant correlation between the differences in the investment into the proteome 
and the difference in growth rates (ρ
s
 = 0.34, p = 0.33). The differences in the allocation of 
resources into the protein compartment of different bacterial strains were therefore not the main 
determinant of variation in their respective generation times. 
Taken together, our results seemed to suggest that the ultimate manifestation of the disruption of 
wild type baseline gene expression by RpoB Ser450Leu was a net increase in the biosynthetic 
input required to maintain the steady state proteome: the greater the cost of the disruption, the 
greater the slowing down of growth in a given strain background. We propose this as the 
“Burden of Expression” hypothesis of the fitness cost of rifampicin resistance. 
Carbon allocation rather than ATP availability modulates cost of resistance 
An implication of the “Burden of expression” hypothesis is the possibility of suppressing the 
emergence of rifampicin-resistance in mycobacteria by maximising the additional biosynthetic 
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cost imposed by the deviation from the baseline expression. We tested two types of conditions 
that may impose such a stress: inhibition of ATP synthesis and variation of carbon-source quality. 
The first would disrupt the ability to generate energy through catabolic processes, while the 
second would place more emphasis on the anabolic aspects of bacterial growth. In the first 
instance, we tested the susceptibility to bedaquiline, an ATP synthase inhibitor that leads to a 
decrease in intracellular ATP levels in Mtb
38
. Given the higher baseline cost of their proteome, we 
expected that RpoB Ser450Leu mutants should show an increased susceptibility to bedaquiline 
commensurate with their relative loss of fitness. We did not observe any correlation between 
bedaquiline susceptibility and the cost of the RpoB Ser450Leu mutation (see Figure 5B).  
Next, we explored varying carbon source quality, expecting substrates that force the bacterial cell 
to rely more heavily on anabolic processes to serve as amplifiers for the perceived cost of 
rifampicin resistance. A related phenotype has been reported before for RpoB Ser450Leu
12
. We 
chose the Luria-Delbrück fluctuation assay as an unbiased readout for the overall increase in the 
cost of rifampicin-resistance, because its frequency of resistance estimate contains a signal for the 
ability of drug resistant bacteria to propagate within the population prior to antibiotic exposure
39
. 
The global increase in the cost of RpoB mutations would therefore manifest itself as an apparent 
decrease in the frequency of resistance, as the population size of pre-existing RpoB mutants 
would be smaller due to limited expansion post-emergence. We chose glycerol, citrate and acetate 
to test our hypothesis in the soil organism Mycobacterium smegmatis, whose patterns of rifampicin 
resistance mirror those of Mtb
40
. As expected, these three carbon sources supported different 
growth rates with measured generation times of the wild type being 3.24 h ( 
95%
CI: 3.23 – 3.25 h), 
6.17 h ( 
95%
CI: 6.09 – 6.25 h) and 17.62 h ( 
95%
CI: 17.61 – 17.62 h), respectively. We then 
determined the frequency of rifampicin resistance for bacteria grown on each carbon source 
using the Luria-Delbrück fluctuation assay. We found a striking correlation between carbon 
source and the calculated frequency of resistance, with bacteria grown in glycerol giving rise to 
rifampicin-resistant bacteria at a rate of 1.3 × 10
-8
 ( 
95%
CI: 1.2 × 10
-8
 – 1.5 × 10
-8
), those grown in 
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citrate at a rate of 3.4 × 10
-9
 ( 
95%
CI: 2.9 × 10
-9
 – 4.0 × 10
-9
)  and acetate-cultured bacteria at a rate 
of 4.5 × 10
-10
 ( 
95%
CI: 3.4 × 10
-10
 – 5.6 × 10
-10
) – see  Figure 5C. This trend was remarkable, 
because it showed that changing only the carbon source, keeping all other variables constant, 
could lead to a 28-fold change in the frequency of resistance. 
The disparity in outcomes between the two experimental approaches suggests that the availability 
of catabolic energy does not disproportionately influence the ability of RpoB mutants to survive. 
However, the impact of carbon source on the frequency of rifampicin-resistant bacteria within a 
population clearly suggests that carbon allocation might be an important driver of the fitness cost 
of rifampicin resistance.  
Discussion 
We normally expect that form follows function in bacteria: expression differences should reflect 
variations in physiological states. Indeed, we show that RpoB Ser450Leu imparted a measurable 
physiological perturbation in addition to conferring rifampicin resistance. Consistent with the 
suggested role of compensatory mutation
18
, we confirmed that in one strain, RpoC Leu516Pro 
reduced both, the apparent fitness cost of rifampicin resistance and the magnitude of the 
expression changes arising from it. However, we also showed that the nature of the perturbation 
was not consistent across different genetic backgrounds. Instead, we observed a strain-specific 
response to the RpoB mutation, both in terms of the relative impact on growth and the 
rearrangement of gene expression. We further observed that the magnitude of the fitness cost 
that RpoB Ser450Leu imposes on a strain was related to the overall increase in the resources 
allocated to the proteome. Based on these observations, we proposed the “Burden of expression” 
hypothesis, with which we posited that in Mtb, the cost of rifampicin resistance was mediated by 
the metabolic burden imposed by the modified baseline protein expression of resistant strains. 
Elaborating on this hypothesis we demonstrated that interfering with anabolic processes could 
suppress the emergence of rifampicin resistance in the related organism M. smegmatis.  
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The “Burden of expression” hypothesis stems from experimental data with clear caveats. First, 
we started our analyses assuming that ribosomal biosynthesis is unlikely to play a key role in the 
cost of rifampicin resistance in Mtb and that therefore expression data were a better window into 
the modified physiology. Our data seem to support the validity of this assumption: ribosomal 
proteins represented only 5.5%, on average, of the total protein biomass in our experiments. This 
proportion was marginally higher in RpoB mutants, and it seemed to increase with increasing 
generation time (see Supplementary Figure 15). These trends were more consistent with a cost 
imposed by the metabolic burden of making ribosomes. Second, some of our key conclusions are 
based on a relatively small number of strains. Nonetheless, to the best of our knowledge, this 
sample set represents the most comprehensive and best curated account of rifampicin resistance-
induced global expression changes in Mtb to date, covering both: evolutionary dynamics and 
phylogenetic diversity. We were also able to show that patterns of expression detected in the DS-
RifR comparison were robust when the same strain pair was sampled again (see Figure 4 and 
Supplementary Figure 7). Importantly, key inferences that led us to propose the hypothesis came 
from SWATH-MS proteomic data drawn from the five different strain backgrounds. These data 
showed a clear clustering of biological replicates (see Supplementary Figure 16), with the 
exception of N0145 for which we were also unable to detect a significant cost for the Ser450Leu 
mutation or any significant changes to the expression. Third, we assumed that label free 
quantification (LFQ) using the “best flyer peptide” or TopN approach, which reflects the 
proportional abundance of individual proteins within our samples
41
, can be used to draw 
conclusions about the resource investment of the cell and can be extended to the growth rate of 
bacteria. It is possible that the roles are reversed and the growth rate of bacteria in fact 
determines the protein complement being expressed
42
. We addressed this possibility by 
performing a comparison of proteome investment and growth rate for wild type strains only. If 
the growth rate of Mtb did indeed determine the protein complement of cells across genetic 
distances on an evolutionary timescale, we would expect a strong correlation between differences 
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in proteome and differences in growth rates between any two strains. This was however not the 
case (see Supplementary Figure 13). Finally, we also assumed that the proteome plays a central 
role in imposing a limit to the growth rate of an Mtb cell. There are other components that 
require considerable investment in carbon: in the case of Mtb both lipids and cell wall may act as 
a sink for resources limiting growth as they can account for over half of the dry mass of actively 
growing cells
43
. Lipidomic analysis of RpoB mutants in Mtb pointed to differences in mycobactin 
biosynthesis as one of the biggest discrepancies between rifampicin-resistant mutants and their 
susceptible ancestors
44
. While echoing a key observation from our quest for determining the cost 
of resistance, we saw no evidence that mycobactin biosynthesis itself changes the rate of bacterial 
growth. The virulence-associated phthiocerol dimycocerosates (PDIM) have also been implicated 
in the cost of rifampicin resistance
45
, as have other changes in lipid composition
46
. The full 
exploration of the role of lipids in the physiology of rifampicin-resistant Mtb is beyond the scope 
of this study, but it would provide an interesting new and complementary avenue to pursue.  
Keeping these considerations in mind, there are two striking features to emerge from our results. 
The first is the pervasive epistasis modulating the impact of RpoB Ser450Leu: the same mutation 
has markedly different effects on the physiology of different Mtb strains. The second is the 
apparent mechanism through which modulation of gene expression is propagated across the 
levels of bacterial physiology. Modification in RNAP function seems to have pleiotropic effects 
that transcend the disruption of any single group of genes, and impart a perturbation that appears 
to affect bacterial resource allocation. 
One question that remains open is what sits at the heart of the disparity in phenotypes? The 
sequence of RNAP is effectively the same in all strains
47
; and by extension so are the biochemical 
changes that arise from resistance
13
. We envisage that part of the answer lays in differences in 
underlying robustness: a strain’s capacity to buffer perturbation. Furthermore, we can consider 
this a window into the evolutionary adaptation of each strain and a sign of how different their 
physiologies really are. The amalgamation of mutational differences that effectively makes up a 
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strain genetic background weaves a baseline phenotype that allows different Mtb strains to be 
successful pathogens despite differences in their underlying physiology. These differences are 
unmasked by the presence of a mutation that sits at the core of gene expression and reveals 
idiosyncratic transcriptional responses to rifampicin resistance that are poorly conserved across 
genetic distances. This observation has the implication that, beyond the described mutations in 
BBDP, which seem to alleviate some of the biochemical and gene expression effects of 
rifampicin resistance more generally, further investigation of positive selection of compensation 
of resistance-related traits should be performed in genetically related strains as they could vary 
considerably when comparing phylogenetically distant strains
21,48
.  
The strain-specific nature of resistance-related expression perturbations can be used to provide a 
credible link to disparate growth rate modulation. Our suggestion that proteome composition 
influences growth rate is not without precedent. This connection has been made before
49
, and 
resulted in the formulation of a collection of “growth laws” that linked growth rates to the 
partitioning of the limited proteome between ribosomes and other proteins carrying out the rest 
of the cellular functions. Growth on different carbon sources impacted this balance, with 
“poorer” ones requiring a greater investment into the functional proteome, presumably because 
of the need for anabolic reactions increased the reliance on biosynthetic enzymes. A similar 
relationship has been observed in a wide range of microbial species
50
. An elaboration of these 
growth relationships also led to the conclusion that the efficiency of proteome allocation can 
impact growth rates and cell physiology
51
. Our finding that the increase in the relative cost of the 
proteome brought about by the gain of a mutation correlates with the relative fitness of that 
mutation is consistent with these reports, as is our observation that anabolic processes may play a 
mechanistic role in setting the cost of a mutation.  
The observed differential cost of rifampicin resistance across Mtb strains, provides a lens through 
which we can better understand the emergence of drug resistance in clinical TB. However, it also 
indicates a new avenue to pursue in the fight against rifampicin resistant Mtb and perhaps 
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uncover a new paradigm for chemotherapeutic intervention. Agents that impart a considerable 
shock to the expression equilibrium of bacteria could exhibit potent activity against rifampicin 
resistant strains due to collateral sensitivity. Furthermore, when given in combination with 
rifampicin, such agents may act to suppress the emergence of resistance; a valuable attribute for 
lengthening the shelf life of rifampicin.  
Methods 
Strains and culture conditions 
We used four strains described by Comas et al.
52
: namely the wild type, clinical isolate T85 
(N0155, DS), a rifampicin resistant mutant of T85 carrying the Ser450Leu mutation (N1981, 
RifR), a derivative of T85 that was evolved by serial passage (200 generations) in the absence of 
rifampicin (N1588, DS
evo
) and an evolved derivative of the rifampicin resistant strains carrying an 
additional mutation in RpoC – Leu516Pro (N1589, RifR
evo
).  
In addition to these strains we used four clinical isolates that are part of the recently compiled 
Reference set of Mtb clinical strains
53
 covering the genetic diversity of Mtb. Two strains belonging 
to Lineage 1 (N0072, N0157) and two to Lineage 2 (N0052, N0145). We plated each of these 
strains on 7H10 plates containing 5 μg/ml Rifampicin, and picked colonies of spontaneous 
mutants. We checked the rifampicin-resistance conferring mutations using Sanger sequencing of 
the amplified RRDR region (Forward primer: TCGGCGAGCTGATCCAAAACCA, Reverse 
primer: ACGTCCATGTAGTCCACCTCAG, product size: 601 bp), and kept a Ser450Leu 
derivative of each clinical strain (N2027, N2030, N2495 and N1888, respectively). 
Bacteria were cultured in 1l bottles containing large glass beads to avoid clumping and 100 ml of 
media incubated at 37°C rotated continuously on a roller. Unless otherwise stated we used a 
modified 7H9 medium supplemented with 0.5% w/v pyruvate, 0.05% v/v tyloxapol, 0.2% w/v 
glucose, 0.5% bovine serum albumin (Fraction V, Roche) and 14.5 mM NaCl. Compared to the 
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usual composition of 7H9 we omitted glycerol, tween 80, oleic acid and catalase from the 
medium. We added 10 μM Hemin (Sigma) when supplementing growth medium with iron. We 
followed growth by measuring optical density at 600 nm (OD
600
).  
Fluctuation assay experiments were performed using Mycobacterium smegmatis, mc
2
 155. M. 
smegmatis was grown either in 10 ml cultures within 50 ml Falcon conical tubes in a shaker 
incubator (37°C, 200RPM), or as 200 μl aliquots within flat-bottomed 96-well plates at 37°C and 
shaken at 200 rpm. We used unmodified 7H9 medium or medium where glycerol was replaced 
with citrate or acetate added at concentrations that matched the molarity of carbon. 
Data availability and data analysis 
All RNAseq data were deposited in the ArrayExpress repository of the European Bioinformatics 
Institute under the E-MTAB-7359 accession. 
Unless otherwise stated, we preformed the analyses using Python 3.5.2 augmented with the 
following modules to provide additional functionality: Matplotlib (ver 2.0.0), Numpy (ver 1.12.1), 
Scipy (ver 0.19.0), Pandas (ver 0.20.1), statsmodels (ver 0.8.0), sklearn (ver 0.18.1), and netwrokX 
(ver 1.11).  
Fitness determination 
Mtb fitness was determined by comparative growth rate estimation. We grew bacteria as 
described and followed their growth by measuring OD
600
. We transformed the optical density 
measurements using logarithm base 2 and trimmed all early and late data points that did deviated 
from the linear correlation expected for exponential growth. Next, we fitted a linear mixed effect 
regression model to the data. Fitness cost was calculated as the resistance imposed deviation from 
wild type growth dynamics. 
For M. smegmatis, we determined the growth rates by culturing bacteria as described above. We 
monitored the increase in OD
600
 using a Tecan M200 Pro Nanoquant at 20 min intervals. The 
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data were log2-transformed, trimmed to retain only the portion of data pertinent to exponential 
growth and used for fitting a mixed effect linear regression model to estimate growth parameters. 
Transcriptional analysis with RNAseq 
We transferred a 40 ml aliquot of bacterial culture in mid-log phase (OD600 = 0.5 ± 0.1) into a 
50ml Falcon conical tube containing 10 ml ice. We harvested the cells by centrifugation (3,000×g, 
7 min, 4°C), re-suspended the pellet in 1 ml of RNApro solution (MP Biomedicals) and 
transferred the suspension to a Lysing matrix B tube (MP Biomedicals). We disrupted the 
bacterial cells using a FastPrep24 homogeniser (40s, intensity setting 6.0, MP Biomedicals). We 
clarified the lysate by centrifugation (12,000×g, 5 min, 4°C), transferred the supernatant to a clean 
tube and added chloroform. We separated the phases by centrifugation (12,000×g, 5 min, 4°C) 
and precipitated the nucleic acids from the aqueous phase by adding ethanol and incubating at -
20C overnight. We performed a second acid phenol extraction to enrich for RNA. We treated 
our samples with DNAse I Turbo (Ambion), and removed stable RNAs by using the RiboZero 
Gram Positive ribosomal RNA depletion kit (Epicentre). We prepared the sequencing libraries 
using the TruSeq stranded Total RNA kit (Illumina) and sequenced on a HiSeq2500 high output 
run (50 cycles, single end).  
Illumina short reads were mapped to the Mtb H37Rv reference genome using BWA (ver 0.7.13); 
the resulting mapping files were processed with samtools (ver 1.3.1). Per-feature read counts were 
performed using the Python module htseq-count (ver 0.6.1p1) and Python (ver 2.7.11). We 
performed differential expression analysis using the R package DESeq2
54
 (ver 1.16.1) and R (ver 
3.4.0). In the case of the identification of the signature of compensation we performed a 
comparison of RifR vs DS + DS
evo
 + RifR
evo
. For the follow-up experiments we performed two 
separate comparisons: (DR
N0072
 + DR
N0157
 + DR
N0052
 + DR
N0145
 + DR
N0155
) vs (DS
N0072
 + DS
N0157
 
+ DS
N0052
 + DS
N0145
 + DS
N0155
) as well as individual DR vs DS comparisons. 
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Gene set enrichment analysis was based on functional annotation from the Kyoto Encyclopaedia 
of Genes and Genomes and a custom collation of curated gene sets based on published reports. 
The overrepresentation analysis was based on Fisher’s exact as the discriminating test. 
In addition we transformed per-feature counts into transcript counts per million bases (TPM). 
TPM for each feature for each sample were calculated using the following formula:  
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Where counts
i
 refers to the number of reads that map to a feature i, and size
i
 refers to the length (in 
bp) of feature i. This ratio was normalized by dividing by the sum of all the ratios across all the 
features.  
Proteomic analysis with SWATH-MS 
We harvested 20 OD
600
 equivalents from mid-log phase (OD
600
 = 0.5 ± 0.1) bacterial cultures by 
centrifugation (3,000×g, 7 min, 4°C). We washed the bacterial pellet twice with phosphate 
buffered saline (PBS) to remove residues of tyloxapol. We re-suspended the bacterial pellet in 500 
μl of protein lysis buffer (8M Urea, 0.1 M Ammonium bicarbonate, 0.1% RapiGest [Waters]) and 
transferred the suspension to a Lysing matrix B tube (MP Biomedicals). We disrupted the 
bacterial cells using a FastPrep24 homogeniser (40s, intensity setting 6.0, MP Biomedicals). We 
clarified the lysate by centrifugation (12,000×g, 5 min, 4°C), and sterilised the supernatant by 
passing it twice through a 0.22 μm syringe filters (Milipore). 
Following protein extraction for each sample, we used trypsin to digest proteins into peptides 
and then desalted them using C
18
 columns (The Nest Group). The cleaned up peptides were re-
suspended in MS buffer (2% v/v acentonitrile, 0.1% v/v formic acid). Finally, the RT-kit 
(Biognosis) containing 11 iRT retention time normalization peptides was spiked in to every 
sample. 
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We measured every sample in sequential window acquisition of all theoretical mass spectra 
(SWATH) mode, a data independent acquisition implementation, on a tripleTOF 5600 mass 
spectrometer (AB Sciex) coupled to a nano flow HPLC system with the gradient of one hour
55
. 
The raw files acquired through a 64 variable width window precursor isolation scheme were 
centroid normalized using Proteowizard msconvert. We used the Mtb spectral library described 
earlier
56
 to extract data using the OpenSWATH workflow
57-59
. The processed data were filtered by 
MAYU to 1% protein FDR
60
. R packages aLFQ and MSstats were used for protein quantification 
(Top3 peptides and top5 fragment ions
41
) and differential expression analysis respectively
61,62
. 
Mycobactin determination 
We harvested 5 OD
600
 equivalents from mid-log phase (OD
600
 = 0.5 ± 0.1) bacterial cultures by 
centrifugation (3,000×g, 7 min, 4°C). We washed the bacterial pellet three times with 15ml of 
cold, sterile 7H9 medium base devoid of additives (BD) to remove residues of tyloxapol. After 
washing we resuspended the pellets in 80 μl of cold, sterile 7H9 medium base and added 750 μl 
of 1:2 Chloroform:Methanol. We vortexed the samples for 5 minutes at top speed and added 750 
μl of Chloroform. The samples were shaken for 1.5h at room temperature and clarified by 
centrifugation (16,000 × g, 10 min). We transferred the organic phase to a fresh tube, dried the 
samples in a speedvac and re-suspended each sample in 120 μl of 44:44:2 
Acetonitrile:Methanol:H2O, (v:v:v). 
Chromatographic separation and analysis by mass spectrometry was done using a 1200 series 
HPLC system with a Phenomenex Kinetex column (1.7 µl × 100 mm × 2.1 mm) with a 
SecurityGuard Ultra (Part No: AJ-9000) coupled to an Agilent Technologies 6550 Accurate-Mass 
Q-Tof. Solvent A: H
2
O, 10mM ammonium acetate; Solvent B: acetonitrile, 10mM ammonium 
acetate. 10 µl of extract were injected and the column (C18) was eluted at 1.125 ml/min. Initial 
conditions were 60% solvent B: 0-2 min, 95% B; 2-4 min, 60% B; 4-5 min at initial conditions. 
Spectra were collected in negative ion mode form 50 – 3200mz. Continuous infusion of 
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/456434doi: bioRxiv preprint first posted online Oct. 30, 2018; 
24 
 
calibrants (Agilent compounds HP-321, HP-921, HP-1821) ensured exact masses over the whole 
mass range. 
We converted the raw data files to the mzML format using msConvert and processed them in R 
using the XCMS
63
 (ver 3.0.2). We extracted targeted ion chromatograms with CAMERA (ver  
1.34.0). 
Transcriptional module analysis. 
The iron-responsive sub-graph of the global gene regulation network published by Peterson et 
al.
28
,  was generated by using all expression modules and all iron-responsive genes as nodes, with 
edges connecting them representing module membership. All other gene nodes were discarded, 
keeping only the information pertinent to the number of genes present in each module (its 
degree). We focused explicitly on modules with at least 3 IdeR-dependent iron-responsive genes 
within them. Finally we marked significant differential expression of the gene nodes in every 
comparison. 
For the purposes of contextualising the expressional profiling of RpoB Ser450Leu we selected a 
subset of expression modules as follows: first we collated all the genes that were differentially 
expressed in at least one genetic background as determined by pairwise comparisons. We then 
scored each expression module for enrichment of membership by differentially expressed genes 
using a binomial test. We retained all modules for which the test pointed to an excess of 
differentially regulated genes (p < 0.05). We constructed a new sub-graph of the global regulatory 
network using all enriched modules and their constituent genes irrespective of whether or not 
individual genes were significantly differentially expressed. Edges reflected module membership. 
We added expression information in the form of log-fold changes of abundance to each 
subgraph based on pairwise analyses. 
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Calculation of genetic distance between clinical isolates 
Genetic distance between strains was defined as the number of single nucleotide variants (SNV) 
that separate two strains. The numeric value of this parameter was extracted from the phylogeny 
published elsewhere
53
. 
Quantification of the relative impact of the rpoB mutation on gene expression in 
different clinical isolates 
We define the dissimilarity in the expressional response to the presence of the rpoB mutation 
using three metrics: absolute number of shared significantly differentially expressed genes, the 
fraction of both the shared significantly differentially expressed genes and shared non-affected 
genes (hamming distance) and the Euclidean distance between ratios of TPM. The first is simply 
the number of shared genes that were found to be significantly affected by the presence of the 
rpoB mutation in two different genetic backgrounds. For the second we use the same input to 
calculate the hamming distance between the patterns of genes significantly affected by the 
mutation in rpoB in two different genetic backgrounds. In the third case we first calculate the 
TPM. We then calculate the mean TPM for each gene across the biological replicates as well as 
the ratio of mutant to wild type mean TPM for every gene. This gives us a vector containing 4000 
ratios for each mutant-wild type pair. Finally we calculate the Euclidean distance between these 
vectors for the different genetic backgrounds. We plotted each of these metrics against genetic 
distance and calculated the spearman correlation and the coefficient of variance: standard 
deviation over mean multiplied by 100 (σ / μ × 100%). 
Quantification of the absolute impact of the rpoB mutation on gene expression of a 
clinical isolate 
We used transcript counts per million bases (TPM) and label free quantification (LFQ) to 
generate an RNA vector and a protein vector containing all the available information for each 
measured sample. We then calculated all the possible DS – RifR pairwise Euclidean distances for 
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the RNA and protein vectors within each genetic background. We used the mean and standard 
deviation for the dissimilarity estimates. We evaluated the correlation between the fitness cost of 
RpoB mutations and the expression distance using the R
2
-coefficient derived from ordinary least 
squares linear regression as well as the Spearman correlation. Arbitrary units expressing the 
dissimilarity were obtained by dividing the calculated distances by 500,000 or 10,000,000 for TPM 
and LFQ, respectively. 
Estimation of the biosynthetic cost of protein production 
The calculation of biosynthetic cost was based on the molecular weight of amino acids (MW)
36
 or 
on the estimate of E. coli ATP investment into individual amino acids derived by Akashi et al.
37
 
using the following formulae: 
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Where the cost of protein i (p
i
) was calculated as the sum of the cost for each constituent amino 
acid (α
j
MW/ATP
) based either on its molecular weight (MW) or ATP investment (ATP) and adjusted 
by the proportional contribution of protein i to the total proteome of sample X (LFQ
i,X
). The 
overall cost of the proteome P for a sample X (P
X
) is expressed as the sum of the costs of 
individual proteins (p). The difference between the biosynthetic investments in the proteome of 
sample X when compared to sample Y was simply: P
X
 – P
Y
. We estimated the biosynthetic 
perturbation of RpoB Ser450Leu within a genetic background, by resampling sample-specific 
proteome costs for DS and RifR with replacement 100-times, and using the median as well as the 
3
rd
 and 98
th
 quantiles to provide the 95% confidence interval. Finally, we quantify the correlation 
with the relative fitness of RpoB Ser450Leu by calculating the Spearman coefficient. 
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Minimum inhibitory concentration determination 
We used the microplate alamar blue assay
64
 to determine the minimum inhibitory concentrations 
of bedaquiline in all drug susceptible and drug resistant strains used in our study. We tested 
bedaquiline using a two-fold dilution series spanning a concentration of 4 ng/ml – 1 µg/ml. 
Fluctuation Assay for determining the frequency of rifampicin resistance 
We used the Luria-Delbrück fluctuation assay
65
 to determine the frequency of rifampicin 
resistance in Mycobacterium smegmatis. Briefly, we inoculated 30 parallel cultures containing 10 ml of 
modified Middlebrook 7H9 medium containing either glycerol, citrate or acetate as the main 
carbon source with 5000 colony forming units of pre-adapted M. smegmatis. We grew the cultures 
to mid-log phase (OD
600
=0.5) at which point we chose three cultures at random for the 
determination of overall population size. We harvested the remaining bacteria by centrifugation 
4000×g for 7 minutes, re-suspended the cellular pellet with 500 µl of fresh Middlebrook 7H9 
medium and plated onto Middlebrook 7H10 solid media supplemented with 200 µg/ml 
Rifampicin. Plates were incubated at 37°C for 3-4 days and scored by counting the resulting 
resistant colonies. We determined the population-wide number of mutants (m) using an in house 
implementation of the Ma-Sandri-Sarkar maximum likelihood estimation
66
, and adjusted it by the 
estimated population size to determine the frequency of resistance. 
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Figure Legends 
Figure 1: Conceptual workflow. A. Two complementary strain sets used for the experiments. Strains 
comprised in the “Evolutionary trajectory of rifampicin resistance” set were derived from a single 
clinical isolate (DS, N0155) by isolation of a Ser450Leu mutant in the lab and the subsequent passage 
for 200 generations in the absence of rifampicin. These strains were used to identify expression 
changes that are reversed by compensation - signature of compensation. The generalizability of our 
finding was checked using the “Genetic diversity strain set” containing five independent clinical 
isolates and their rifampicin-resistant derivatives. All rifampicin resistant strains shared the same 
resistance mutation – RpoB Ser450Leu. B. Experimental outline for the sampling and analyses. 
Figure 2: Signature of compensation. A. The relative fitness of drug resistant strains (DR) is 
expected to be lower than wild type (DS) at first, but then is expected to increase due to compensatory 
evolution. The phenotypic equivalent of this trend is illustrated as an increase/decrease in a 
measurable trait upon the emergence of resistance that is then returned to its previous level through 
compensation. We refer to this dynamic as the “Signature of Compensation”. B. Plot of transcript 
counts per million bases (TPM) and label free quantifications (LFQ) of cellular proteins for genes 
whose expression is perturbed by the Ser450Leu mutation in RpoB and returned to wild type in the 
presence of the compensating Leu516Pro mutation. All results were standardized across 
measurements for a single gene to allow the comparison between strains. Grey traces show genes 
that are significantly more highly expressed in RifR, yellow traces show genes that were significantly 
less highly expressed in RifR. The red and blue bold lines show the median of the sample for more 
and less highly expressed proteins, respectively. 
Figure 3: RifR has a higher baseline level of mycobactin biosynthesis than DS. A. Subset of the 
gene regulatory network28 containing iron responsive genes. Circles represent IdeR-regulated genes 
that are either induced (black inner circle) or repressed (white inner circle) in low iron conditions. 
Hexagons represent IdeR-independent iron responsive genes that are induced (white inner hexagons) 
or repressed (black inner hexagons) in low iron conditions. We used blue and red to indicate 
significantly lower or higher RNA expression in RifR, respectively. Diamonds represent transcriptional 
modules as defined by Petersen et al, black diamonds indicate modules that contain at least 3 IdeR-
responsive genes. Edges connect gene nodes with the module nodes they belong to. Labels 1-7 refer 
to Module 502 (1), Module 525 (2), Module 267 (3), Module 446 (4), Module 231 (5), Module 086 (6) 
and Module 295 (7) from the original publication.  B. Relative mycobactin levels expressed as 
maximum peak heights for DS and RifR in normal medium (grey dots) and iron-supplemented medium 
(10µM hemin, red dots). Unfilled circles represent the mean of the observations. 
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Figure 4:  The prominent role of mycobactin biosynthesis in the signature of compensation is 
not universal. A. Iron-responsive subset the of gene regulatory network, as shown in Figure 3, 
coloured based on transcriptional differential expression data from pairwise comparison of genetically 
distinct rifampicin-susceptible clinical isolates and their cognate RpoB Ser450Leu mutants. RifR and 
N0155 refer to an independent sampling of the same strain pairs. See Supplementary Figure 7 for the 
proteome counterpart of this plot. B. Representation of the enrichment of significantly differentially 
expressed genes within individual transcriptional modules, as defined by Peterson et al.28. The 
columns alternate proteomic (P) and transcriptomic data (R). “ALL” refers to the global differential 
expression analysis of all rifampicin-susceptible against all rifampicin-resistant strains. The remaining 
column annotations refer to individual pair-wise comparisons in different genetic backgrounds. Black 
squares represent no significant enrichment, mauve squares and yellow squares show enrichment at 
0.01<p<0.05 and p<0.01 using a Fisher’s exact test. These p-values are not adjusted for multiple 
testing. Modules covering the DosR-regulon and IdeR-iron repressed regulon are highlighted 
separately. 
Figure 5:  The fitness cost of RpoB Ser450Leu correlates with increased resource 
requirements. A. The relative fitness of Ser450Leu RpoB mutants estimated from growth rate data is 
negatively correlated with the magnitude of the deviation from the resources allocated to the wild type 
proteome. ϱs – Spearman correlation. B. Comparison of minimum inhibitory concentrations (MIC) of 
bedaquiline in clinical isolates and their cognate RpoB mutants. Dotted line shows parity, darker 
shading includes 50% or lower difference in MIC and the lighter shading spans up to 2-fold change in 
MIC. C. The frequency of rifampicin resistance as measured in the model organism Mycobacterium 
smegmatis with the Luria-Delbrück fluctuation assay is plotted against the generation time in media 
containing different carbon sources. 
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